NCT06794008View on ClinicalTrials.gov

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 26, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 31, 2027

Conditions
Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)ANCA-associated VasculitisIgG4-Related DiseasesAntiphospholipid SyndromeAcquired Thrombotic Thrombocytopenic PurpuraBehcet DiseaseSjogren Syndrome
Interventions
DRUG

BCMA-CD19 CAR-T therapy

Patients received the BCMA-CD19-targeted CAR-T cells with a dosage of 3×10\^6/kg CAR-T cells per kilogram.

Trial Locations (1)

100044

RECRUITING

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER